Premium
Transient receptor potential vanilloid 1 ( TRPV 1), TRPV 4, and the kidney
Author(s) -
Kaßmann M.,
Harteneck C.,
Zhu Z.,
Nürnberg B.,
Tepel M.,
Gollasch M.
Publication year - 2013
Publication title -
acta physiologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.591
H-Index - 116
eISSN - 1748-1716
pISSN - 1748-1708
DOI - 10.1111/apha.12051
Subject(s) - trpv , transient receptor potential channel , trpv1 , trpv4 , chemistry , capsaicin , pharmacology , medicine , receptor , biochemistry
Recent preclinical data indicate that activators of transient receptor potential channels of the vanilloid receptor subtype 1 ( TRPV 1) may improve the outcome of ischaemic acute kidney injury ( AKI ). The underlying mechanisms are unclear, but may involve TRPV 1 channels in dorsal root ganglion neurones that innervate the kidney. Recent data identified TRPV 4, together with TRPV 1, to serve as major calcium influx channels in endothelial cells. In these cells, gating of individual TRPV 4 channels within a four‐channel cluster provides elementary calcium influx (calcium sparklets) to open calcium‐activated potassium channels and promote vasodilation. The TRPV receptors can also form heteromers that exhibit unique conductance and gating properties, further increasing their spatio‐functional diversity. This review summarizes data on electrophysiological properties of TRPV 1/4 and their modulation by endogenous channel agonists such as 20‐HETE, phospholipase C and phosphatidylinositide 3‐kinase ( PI 3 kinase). We review important roles of TRPV 1 and TRPV 4 in kidney physiology and renal ischaemia reperfusion injury; further studies are warranted to address renoprotective mechanism of vanilloid receptors in ischaemic AKI including the role of the capsaicin receptor TRPV 1 in primary sensory nerves and/or endothelium. Particular attention should be paid to understand the kidneys' ability to respond to ischaemic stimuli after catheter‐based renal denervation therapy in man, whereas the discovery of novel pharmacological TRPV modulators may be a successful strategy for better treatment of acute or chronic kidney failure.